Clinical and phylogenetic influenza dynamics for the 2019-20 season in the global influenza hospital surveillance network (GIHSN) - Pilot study.


Journal

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
ISSN: 1873-5967
Titre abrégé: J Clin Virol
Pays: Netherlands
ID NLM: 9815671

Informations de publication

Date de publication:
07 2022
Historique:
received: 03 02 2022
revised: 21 04 2022
accepted: 11 05 2022
pubmed: 21 5 2022
medline: 15 6 2022
entrez: 20 5 2022
Statut: ppublish

Résumé

The Global Influenza Hospital Surveillance Network (GIHSN) has operated with the aim of investigating epidemiological and clinical factors related to severe influenza-related hospitalisations. A common GIHSN core protocol for prospective patient enrolment was implemented. Hospital personnel completed a standardized questionnaire regarding the included patients' medical history, compiled a hospitalisation summary, collected an upper respiratory swab sample for laboratory diagnosis, and genome sequencing was performed for a subset of samples. Patient data were compared according to influenza subtype, lineage, and phylogenetic groups using the Fisher's exact test. From September 2019 to May 2020, 8791 patients aged ≥5 years were included. Among them, 3021 (34.4%) had a laboratory-confirmed influenza diagnosis. Influenza A(H1N1)pdm09 dominated the season among all age groups, while the B/Victoria-like lineage accounted for over half of the infections among younger age groups (5-49 years). Sequencing of the hemagglutinin segment was possible for 623 samples and revealed an influenza A and B clade frequency among severe influenza hospitalisations similar to other medically attended surveillance networks, such as the WHO GISRS. No phylogenetic clustering was observed among hemagglutinin substitutions depending on the administration of supplemental oxygen or vaccine failure. The GIHSN confirms its ability as an international hospital-based active surveillance network to provide valuable information on influenza infection dynamics in hospital settings. Increasing the number of participating sites and compiling more complete data, such as genome sequencing, will allow the exploration of associations between viral factors, vaccine protection, and disease severity.

Sections du résumé

BACKGROUND
The Global Influenza Hospital Surveillance Network (GIHSN) has operated with the aim of investigating epidemiological and clinical factors related to severe influenza-related hospitalisations.
STUDY DESIGN
A common GIHSN core protocol for prospective patient enrolment was implemented. Hospital personnel completed a standardized questionnaire regarding the included patients' medical history, compiled a hospitalisation summary, collected an upper respiratory swab sample for laboratory diagnosis, and genome sequencing was performed for a subset of samples. Patient data were compared according to influenza subtype, lineage, and phylogenetic groups using the Fisher's exact test.
RESULTS
From September 2019 to May 2020, 8791 patients aged ≥5 years were included. Among them, 3021 (34.4%) had a laboratory-confirmed influenza diagnosis. Influenza A(H1N1)pdm09 dominated the season among all age groups, while the B/Victoria-like lineage accounted for over half of the infections among younger age groups (5-49 years). Sequencing of the hemagglutinin segment was possible for 623 samples and revealed an influenza A and B clade frequency among severe influenza hospitalisations similar to other medically attended surveillance networks, such as the WHO GISRS. No phylogenetic clustering was observed among hemagglutinin substitutions depending on the administration of supplemental oxygen or vaccine failure.
CONCLUSIONS
The GIHSN confirms its ability as an international hospital-based active surveillance network to provide valuable information on influenza infection dynamics in hospital settings. Increasing the number of participating sites and compiling more complete data, such as genome sequencing, will allow the exploration of associations between viral factors, vaccine protection, and disease severity.

Identifiants

pubmed: 35594785
pii: S1386-6532(22)00117-2
doi: 10.1016/j.jcv.2022.105184
pii:
doi:

Substances chimiques

Hemagglutinins 0
Influenza Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

105184

Informations de copyright

Copyright © 2022. Published by Elsevier B.V.

Auteurs

Grégory Quéromès (G)

CIRI, Centre International de Recherche en Infectiologie, Team VirPatH, Univ Lyon, Inserm, U1111, CNRS, UMR5308, Universit Claude Bernard Lyon 1, ENS de Lyon, Lyon F-69007, France.

Emilie Frobert (E)

CIRI, Centre International de Recherche en Infectiologie, Team VirPatH, Univ Lyon, Inserm, U1111, CNRS, UMR5308, Universit Claude Bernard Lyon 1, ENS de Lyon, Lyon F-69007, France; Laboratoire de Virologie, Institut des Agents Infectieux (IAI), Hospices Civils de Lyon, 103 Grande Rue de la Croix-Rousse, Lyon 69317 CEDEX 04, France.

Elena Burtseva (E)

Ministry of Health of the Russian Federation, FSBI "N.F. Gamaleya NRCEM", Moscow, Russian Federation.

Anca Drăgănescu (A)

Matei Bals National Institute for Infectious Diseases, Bucharest, Romania.

Paravaiz A Koul (PA)

Internal and Pulmonary Medicine, Sher-i-Kashmir Institute of Medical Sciences, Jammu and Kashmir, Srinagar, India.

Andrey Komissarov (A)

National Influenza Centre, Smorodintsev Research Institute of Influenza, Saint Petersburg, Russian Federation.

V Alberto Laguna-Torres (VA)

Tropical Medicine Institute, San Marcos University and Clinica Internacional, Lima, Perú.

Jason Leblanc (J)

Division of Microbiology, Department of Pathology and Laboratory Medicine, Nova Scotia Health (NSH), Halifax, Nova Scotia, Canada.

F-Xavier López-Labrador (FX)

Virology Laboratory, Genomics and Health Area, FISABIO - Public Health, Generalitat Valenciana, Valencia, Spain; CIBERESP, Instituto de Salud Carlos III, Madrid, Spain.

Snežana Medić (S)

Department of Epidemiology, Faculty of Medicine, University of Novi Sad, Novi Sad 21000, Serbia; Center for Disease Control and Prevention, Institute of Public Health of Vojvodina, Novi Sad, Serbia.

Alla Mironenko (A)

Department of Respiratory and other Viral Infections, L.V.Gromashevsky Institute of Epidemiology & Infectious Diseases NAMS of Ukraine, Kyiv, Ukraine.

Nancy A Otieno (NA)

Kenya Medical Research Institute - Center for Global Health Research, Kisumu, Kenya.

Guillermo M Ruiz-Palacios (GM)

Department of Infectious Diseases, National Institute of Medical Sciences and Nutrition Salvador Zubiran, Mexico City, Mexico.

Tanriover Md (T)

Hacettepe University Faculty of Medicine, Ankara, Turkey; Turkish Society of Internal Medicine, Ankara, Turkey.
CIRI, Centre International de Recherche en Infectiologie, Team VirPatH, Univ Lyon, Inserm, U1111, CNRS, UMR5308, Universit Claude Bernard Lyon 1, ENS de Lyon, Lyon F-69007, France.
CIRI, Centre International de Recherche en Infectiologie, Team VirPatH, Univ Lyon, Inserm, U1111, CNRS, UMR5308, Universit Claude Bernard Lyon 1, ENS de Lyon, Lyon F-69007, France.

Laurence Josset (L)

CIRI, Centre International de Recherche en Infectiologie, Team VirPatH, Univ Lyon, Inserm, U1111, CNRS, UMR5308, Universit Claude Bernard Lyon 1, ENS de Lyon, Lyon F-69007, France; Laboratoire de Virologie, Institut des Agents Infectieux (IAI), Hospices Civils de Lyon, 103 Grande Rue de la Croix-Rousse, Lyon 69317 CEDEX 04, France.

Bruno Lina (B)

Laboratoire de Virologie, Institut des Agents Infectieux (IAI), Hospices Civils de Lyon, 103 Grande Rue de la Croix-Rousse, Lyon 69317 CEDEX 04, France; Centre National de Référence des virus des infections respiratoires dont la grippe, Lyon, France. Electronic address: bruno.lina@chu-lyon.fr.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH